Articles Highlight Scientific and Economic Advantages Provided by Precipio’s Technology
NEW HAVEN, CT, (October 18th, 2018) – The scientific and economic advantages of the proprietary, ultra-sensitive ICE-COLD PCR (ICP) technology developed by specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO) were recently spotlighted in several industry media outlets.
A Drug Delivery Business News article titled “Tracking tumors with Precipio’s liquid biopsy tech” discusses the role liquid biopsies can play in cancer treatment and why the economics of monitoring is important. To read the article in its entirety, please visit: https://www.drugdeliverybusiness.com/tracking-tumors-with-precipios-liquid-biopsy-tech/
A Clinical Lab Products article titled “Inside Track: In the Trenches” provides a Q&A with Precipio CEO Ilan Danieli. Mr. Danieli discusses the challenges leading to the current state of development for liquid biopsies, evaluates the steps leading to quicker adoption of these tests, and notes the importance of clinical utility and cost-efficient technology, such as those offered by ICP. To read the article in its entirety, please visit: http://www.clpmag.com/2018/09/inside-track-trenches/
A BioSpace article titled “As Liquid Biopsies Grow, Who’s Going to Pay?” discusses the economics of liquid biopsies as well as two specific advantages presented by ICP technology: its cost advantages compared to other commercially available screening technologies; and the flexibility with which ICP test panels can be custom-designed. To read the article in its entirety, please visit: https://www.biospace.com/article/fd1a-as-liquid-biopsies-grow-who-s-going-to-pay-/
The articles at the links above are provided for informational purposes only.
Precipio has built a platform designed to eradicate the problem of misdiagnosis by harnessing the intellect, expertise and technology developed within academic institutions and delivering quality diagnostic information to physicians and their patients worldwide. Through its collaborations with world-class academic institutions specializing in cancer research, diagnostics and treatment such as the Yale School of Medicine and Harvard’s Dana-Farber Cancer Institute, Precipio offers a new standard of diagnostic accuracy enabling the highest level of patient care. For more information, please visit www.precipiodx.com.
Certain statements in this press release constitute “forward-looking statements,” within the meaning of federal securities laws, including statements related to ICP technology, including financial projections related thereto and potential market opportunity, plans and prospects and other statements containing the words “anticipate,” “intend,” “may,” “plan,” “predict,” “will,” “would,” “could,” “should,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the known risks, uncertainties and other factors described in the Company’s definitive proxy statement filed on May 29, 2018, the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2018 and on the Annual Report on Form 10-K for the year ended December 31, 2017 as well as the Company’s prior filings and from time to time in the Company’s subsequent filings with the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. All information in this press release is as of the date of the release and the Company does not undertake any duty to update this information, including any forward-looking statements, unless required by law.